Overcharging by drug firms- Rs 890 crore recovered till now, Minister informs Parliament

Published On 2018-08-01 05:45 GMT   |   Update On 2018-08-01 05:45 GMT

Demand notices have been issued for a total amount of Rs 6,058.07 crore. Amount to the tune of Rs 829.88 crore has been recovered from the companies...in overcharging cases


New Delhi: Government has recovered Rs 830 crore as fine from pharmaceutical companies for overcharging till May 2018, Lok Sabha was informed.


Since the inception of National Pharmaceutical Pricing Authority (NPPA) till May this year, 1,794 demand notices were issued to drug companies for overcharging patients, Union Minister Mansukh L Mandaviya said in a written reply to the House.

"Demand notices have been issued for a total amount of Rs 6,058.07 crore. Amount to the tune of Rs 829.88 crore has been recovered from the companies...in overcharging cases," he added.

In a separate reply, the minister of state for chemicals and fertilizers said exports of generic drugs in 2017-18 stood at USD 12.9 billion. The global generic market in the same period stood at USD 302 billion.

The total pharma exports including bulk drugs, formulations, herbal products and surgical stood at USD 17.27 billion in 2017-18, Mandaviya said.

He said the government is taking a lot of steps to encourage the use of generic drugs in the domestic market.

"The use of unbranded generics is on the rise in the country and it is now estimated at 7 percent of the domestic market share," he said.

In another reply, he said the government had constituted an inter-ministerial committee on November 7, 2013, to suggest ways and means to fix the prices of patented drugs in the country.
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News